Regulators in PREFER

To ensure the regulatory perspective is present throughout the project, we have created a regulatory stakeholder advisory group.

The project will include interviews and focus groups with European and US regulators. Information from these interviews and focus groups will be used when choosing methods to be tested in case studies.


PREFER has formalised a structure for regulatory input to to the project with a stakeholder advisory group, where input is coordinated by the European Medicines Agency (EMA). This regulatory advisory group will not be responsible for the recommendations at the end of the project.This group includes:





  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.


The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).